Thelansis

 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with an unfavorable prognosis. It predominantly manifests with cutaneous lesions, which are frequently asymptomatic and can range from solitary to multiple, covering a wide area. These skin manifestations can vary from bruise-like discolorations to plaques or nodules. Additionally, patients may exhibit bone marrow involvement, infiltration of the central nervous system (CNS), lymph node enlargement, spleen enlargement, and various degrees of cytopenias. Within the dendritic cell and histiocytic neoplasms category, BPDCN is grouped alongside plasmacytoid dendritic cell proliferation associated with myeloid neoplasms. BPDCN primarily affects older men, with a male-to-female ratio ranging from 3:1 to 5:1, typically diagnosed between 60 and 70. The most common initial clinical presentation of BPDCN involves asymptomatic skin lesions, occurring in approximately 90% of patients at diagnosis. Th